San Francisco, California, United States

The program is designed to evaluate the multiple clinical presentations of insulin resistance including disorders in all ages and in both genders: PCOS, atherosclerosis, cardiovascular disease, liver abnormalities, glucose disturbance, breathing & sleep disorders, hypertension, dyslipidemia, cancer, skin, the brain, chronic kidney disease, diabetes and congestive heart failure. It will focus on obesity, incretin, gut hormones, insulin leptin and the brain. The goals of the meeting are to connect bench research to bedside clinical treatment and to recognize that cardiovascular morbidity and mortality, are the common outcome of the many clinical faces of insulin resistance. Upon completion of this meeting, participants should be able to:

1.  Explain the role of insulin resistance (IR) in liver disease, PCOS, CHF, kidney disease and the development of certain cancers.

2.  Appreciate the impact of the world wide obesity, diabetes and metabolic syndrome epidemics particularly in children and special populations.

3.  Realize that insulin resistance may identify which people, especially obese, are at risk to developing metabolic disorders.

4.  Understand the comprehensive approach to the treatment of obesity, hypertension, dyslipidemia and prevention of cardiovascular disease.

5.  Describe the unique role of incretin and gut hormones in metabolic systems and energy balance.

6.  Discuss the relationship between incretin, bile acid, gut hormones to the brain in the management of energy expenditure and storage.

7.  Describe the relationship of IR to obesity and the fat cell.

8.  Relate the potential relationship of IR to circadian rhythm, sleep disorders, the brain, incretin hormones and metabolic disorders.

9.  Diagnose people at a higher risk to developing diabetes, CVD and other metabolic disorders.

10.  Understand potential therapeutic modalities and their complexities in the treatment of these metabolic disorders.